Picture: 123RF/OSTARIYANOV
Picture: 123RF/OSTARIYANOV

Exactly one week since the one-million doses of the Oxford AstraZeneca vaccine from the Serum Institute of India landed in the country, we are haunted by the phrase: “All our spike proteins in one basket”.

In a worrying development, SA’s vaccine rollout was dealt a blow at the weekend after new evidence emerged that AstraZeneca’s vaccine does not protect people against mild to moderate disease caused by the new variant detected in SA late in 2020.

Michael Avery talks to Biovac CEO Dr Morena Makhoana; Stavros Nicolaou, head of the health working group for B4SA; and Patrick Tippoo, director at the African Vaccine Manufacturing Initiative, about these developments and how they affect the vaccine rollout strategy broadly.

Michael Avery talks to a panel about the delay in SA’s vaccine rollout.

Or listen to the full audio:

Subscribe for free episodes: iono.fm | Apple PodcastsSpotify | Pocket Casts | Player.fm

Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.